{"id":"trovax","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00325507","NCT01556841","NCT00448409","NCT02390063","NCT00227474","NCT00521274","NCT00083941","NCT00397345","NCT00445523","NCT01194960","NCT01569919","NCT00259844"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Trovax","companyId":"oxford-biomedica","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Biologic","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Oxford BioMedica","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Trovax","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00325507","phase":"Phase 2","title":"Safety, Immunology, and Biological Activity Evaluation of TroVax® in Treatment of Patients With Locally Advanced or Metastatic Renal Carcinoma","status":"COMPLETED","sponsor":"Oxford BioMedica","isPivotal":false,"enrollment":25,"indication":"Carcinoma, Renal Cell","completionDate":"2008-07"},{"nctId":"NCT01556841","phase":"Phase 2","title":"A Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"University College, London","isPivotal":false,"enrollment":94,"indication":"Ovarian Cancer, Fallopian Tube Cancer","completionDate":"2019-04-19"},{"nctId":"NCT00448409","phase":"Phase 2","title":"A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","isPivotal":false,"enrollment":27,"indication":"Prostatic Neoplasms","completionDate":"2007-05"},{"nctId":"NCT02390063","phase":"Phase 1","title":"A Randomized Phase I Study to Determine the Safety and Immunogenicity of ChAd-MVA Vaccination Compared to MVA Alone With and Without Low Dose Cyclophosphamide in Low and Intermediate Risk Localised Pr","status":"COMPLETED","sponsor":"University of Oxford","isPivotal":false,"enrollment":40,"indication":"Prostate Cancer","completionDate":"2019-05-15"},{"nctId":"NCT00227474","phase":"Phase 2","title":"S0348: A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":0,"indication":"Breast Cancer","completionDate":""},{"nctId":"NCT00521274","phase":"Phase 2","title":"A Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (HRPC)","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","isPivotal":false,"enrollment":11,"indication":"Prostatic Neoplasms","completionDate":"2008-08"},{"nctId":"NCT00083941","phase":"Phase 2","title":"Clinical Trial Phase II (Single Centre Study) : A Preliminary Study of the Safety, Immunogenicity, and Clinical Efficacy of TroVax Given in Conjunction With Interleukin 2 (IL-2) in the Treatment of St","status":"COMPLETED","sponsor":"Oxford BioMedica","isPivotal":false,"enrollment":25,"indication":"Carcinoma, Renal Cell","completionDate":"2008-07"},{"nctId":"NCT00397345","phase":"Phase 3","title":"Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenoca","status":"COMPLETED","sponsor":"Oxford BioMedica","isPivotal":true,"enrollment":733,"indication":"Clear Cell Renal Carcinoma","completionDate":"2009-12"},{"nctId":"NCT00445523","phase":"Phase 2","title":"A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","isPivotal":false,"enrollment":28,"indication":"Carcinoma, Renal Cell","completionDate":"2008-02"},{"nctId":"NCT01194960","phase":"Phase 2","title":"A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer","status":"TERMINATED","sponsor":"Oxford BioMedica","isPivotal":false,"enrollment":25,"indication":"Hormone Refractory Prostate Cancer","completionDate":"2013-03"},{"nctId":"NCT01569919","phase":"Phase 2","title":"A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma","status":"UNKNOWN","sponsor":"Wales Cancer Trials Unit","isPivotal":false,"enrollment":26,"indication":"Malignant, Pleural","completionDate":"2014-12"},{"nctId":"NCT00259844","phase":"Phase 2","title":"A Phase 2 Study Immunologically Evaluating 5T4-MVA (TroVax) in Patients Undergoing Surgical Resection of Colorectal Liver Metastases","status":"COMPLETED","sponsor":"Cancer Research UK","isPivotal":false,"enrollment":20,"indication":"Colorectal Neoplasms","completionDate":"2006-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Biologic","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}